YaoGeJu

Company directoryChina company filings

Zhejiang East-Asia Pharmaceutical Co., Ltd.

As of 18 November 2026, for the company name Zhejiang East-Asia Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 6 active records with this name as holder; 19 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

15 acceptance records as first applicant, grouped into 11 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Tedizolid Phosphate Tablets 2 records · Latest accepted 2026/06/12

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601396Generic2026/06/12Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
CYHS2404355Generic2024/12/14Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Baricitinib Tablets 1 records · Latest accepted 2026/02/06

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600397Generic2026/02/06Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
厄多司坦胶囊 · No verified English name 1 records · Latest accepted 2025/10/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503693Generic2025/10/16Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Mosapride Citrate Tablets 2 records · Latest accepted 2025/07/19

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2502606Generic2025/07/19Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
CYHS2502605Generic2025/07/19Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Trimebutine Maleate Tablets 2 records · Latest accepted 2025/03/29

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501232Generic2025/03/29Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
CYHS2501231Generic2025/03/29Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Epalrestat Tablets 1 records · Latest accepted 2024/10/12

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403407Generic2024/10/12Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Vonoprazan Fumarate Tablets 2 records · Latest accepted 2024/08/16

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402677Generic2024/08/16Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
CYHS2402676Generic2024/08/16Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Agomelatine Tablets 1 records · Latest accepted 2024/08/15

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402659Generic2024/08/15Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets 1 records · Latest accepted 2024/08/08

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402534Generic2024/08/08Zhejiang East-Asia Pharmaceutical Co., Ltd.; Ningbo Shuang Cheng Pharma Co., Ltd. romanizedCDE ↗
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets 1 records · Latest accepted 2024/08/08

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402533Generic2024/08/08Zhejiang East-Asia Pharmaceutical Co., Ltd.; Ningbo Shuang Cheng Pharma Co., Ltd. romanizedCDE ↗
Levofloxacin Tablets 1 records · Latest accepted 2023/12/30

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2303685Generic2023/12/30Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗

Changes in the last 90 days

4 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Marketing application approved: 2 applicationsNo longer listed under review: 2 applications

  1. 2026/11/10Marketing application approved

    Trimebutine Maleate Tablets

    CYHS2501232 · 国药准字H20266547

    Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14

    View source · Table row 52 ↗
  2. 2026/11/10Marketing application approved

    Trimebutine Maleate Tablets

    CYHS2501231 · 国药准字H20266546

    Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14

    View source · Table row 51 ↗
  3. 2026/10/27No longer listed under review

    Trimebutine Maleate Tablets

    CYHS2501232

    Fact date: 2026/10/27 · Date added to this site: 2026/10/27

    Accepted: 2025/03/29

    no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/13 (approval no.: 国药准字H20266547; approval date: 2026/11/10) · NMPA source · row 52

    NMPA · Table row 52 ↗ View source ↗
  4. 2026/10/27No longer listed under review

    Trimebutine Maleate Tablets

    CYHS2501231

    Fact date: 2026/10/27 · Date added to this site: 2026/10/27

    Accepted: 2025/03/29

    no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/13 (approval no.: 国药准字H20266546; approval date: 2026/11/10) · NMPA source · row 51

    NMPA · Table row 51 ↗ View source ↗

Under review

6 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Tedizolid Phosphate Tablets CYHS2601396Generic2026/06/12Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Baricitinib Tablets CYHS2600397Generic2026/02/06Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
厄多司坦胶囊 · No verified English name CYHS2503693Generic2025/10/16Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Mosapride Citrate Tablets CYHS2502606Generic2025/07/19Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Mosapride Citrate Tablets CYHS2502605Generic2025/07/19Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗
Agomelatine Tablets CYHS2402659Generic2024/08/15Zhejiang East-Asia Pharmaceutical Co., Ltd.CDE ↗

Catalogue holder records

6 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Saxagliptin and Metformin Hydrochloride Sustained-release TabletsZhejiang East-Asia Pharmaceutical Co., Ltd.Ningbo Shuang Cheng Pharma Co., Ltd. romanized国药准字H202635292026/03/10Generic approved under the new chemical-drug registration classificationCDE ↗
Vonoprazan Fumarate TabletsZhejiang East-Asia Pharmaceutical Co., Ltd.Zhejiang East-Asia Pharmaceutical Co., Ltd.国药准字H202634482026/02/25Generic approved under the new chemical-drug registration classificationCDE ↗
Vonoprazan Fumarate TabletsZhejiang East-Asia Pharmaceutical Co., Ltd.Zhejiang East-Asia Pharmaceutical Co., Ltd.国药准字H202634472026/02/25Generic approved under the new chemical-drug registration classificationCDE ↗
Levofloxacin TabletsZhejiang East-Asia Pharmaceutical Co., Ltd.Zhejiang East-Asia Pharmaceutical Co., Ltd.国药准字H202544752025/06/10Generic approved under the new chemical-drug registration classificationCDE ↗
Epalrestat TabletsZhejiang East-Asia Pharmaceutical Co., Ltd.Zhejiang East-Asia Pharmaceutical Co., Ltd.国药准字H202647232026/06/10Generic approved under the new chemical-drug registration classificationCDE ↗
Saxagliptin and Metformin Hydrochloride Sustained-release TabletsZhejiang East-Asia Pharmaceutical Co., Ltd.Ningbo Shuang Cheng Pharma Co., Ltd. romanized国药准字H202635512026/03/10Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

19 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
艾拉莫德 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20250001037I2025/11/05CDE ↗
多奈哌齐 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20250000220I2025/04/16CDE ↗
布立西坦 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20250000038A2026/10/10CDE ↗
枸橼酸莫沙必利 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20230000097A2025/01/21CDE ↗
盐酸西那卡塞 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20220001242A2026/08/18CDE ↗
卢立康唑 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20210000095A2025/08/06CDE ↗
非布司他 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20200000264A2022/11/04CDE ↗
盐酸左氧氟沙星 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190009849A2025/04/02CDE ↗
左氧氟沙星 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190009576A2024/12/10CDE ↗
酮康唑 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190009560A2025/11/22CDE ↗
氧氟沙星 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190009341A2025/04/24CDE ↗
盐酸特比萘芬 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190008903A2023/03/24CDE ↗
氯雷他定 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190008454A2024/12/07CDE ↗
马来酸曲美布汀 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190004236A2026/08/18CDE ↗
厄多司坦 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20190002487A2026/07/03CDE ↗
左氧氟沙星 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20170002036A2026/11/05CDE ↗
依帕司他 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20170001298A2026/02/24CDE ↗
富马酸替诺福韦二吡呋酯 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20170001247A2023/09/06CDE ↗
奥美沙坦酯 · No verified English nameZhejiang East-Asia Pharmaceutical Co., Ltd.Y20170001089A2024/08/28CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.